Advances in pediatric asthma in 2010: Addressing the major issues - 10/08/11
![](/templates/common/images/mail.png)
![](/templates/common/images/entites/lowast.gif)
Abstract |
Last year’s “Advances in pediatric asthma” concluded with the following statement: “If we can close these [remaining] gaps through better communication, improvements in the health care system and new insights into treatment, we will move closer to better methods to intervene early in the course of the disease and induce clinical remission as quickly as possible in most children.” This year’s summary will focus on recent advances in pediatric asthma that take steps moving forward as reported in Journal of Allergy and Clinical Immunology publications in 2010. Some of these recent reports show us how to improve asthma management through steps to better understand the natural history of asthma, individualize asthma care, reduce asthma exacerbations, and manage inner-city asthma and some potential new ways to use available medications to improve asthma control. It is clear that we have made many significant gains in managing asthma in children, but we have a ways to go to prevent asthma exacerbations, alter the natural history of the disease, and reduce health disparities in asthma care. Perhaps new directions in personalized medicine and improved health care access and communication will help maintain steady progress in alleviating the burden of this disease in children, especially young children.
Le texte complet de cet article est disponible en PDF.Key words : Asthma, asthma control, asthma impairment, asthma risk, asthma severity, early intervention in asthma, biomarkers, genetics, inhaled corticosteroids, leukotriene receptor antagonists, long-acting β-adrenergic agonists, omalizumab, personalized medicine, therapeutics
Abbreviations used : AHR, ALOX5AP, CAMP, CARE, EBC, FEF25-75, FeNO, FOXP3, GWAS, HRV, ICAC, ICS, IL2RA, IUS, LABA, LO, LTRA, MMP, NHLBI, NIAID, NNF, PM2.5, RSV, SARP, SNP
Plan
Supported in part by Public Health Services Research Grants HR-16048, HL64288, HL 51834, AI-25496, HL081335, and HL075416, and the Colorado Cancer, Cardiovascular and Pulmonary Disease Program. Also supported in part by Colorado CTSA grant 1 UL1 RR025780 from the National Institutes of Health (NIH) and the National Center for Research Resources (NCRR). |
|
Disclosure of potential conflict of interest: S. J. Szefler has consulted for GlaxoSmithKline, Genentech, Merck, Boehringer-Ingelheim, Novartis, and Schering-Plough and has received research support from the National Institutes of Health; National Heart, Lung, and Blood Institute; National Institute of Allergy and Infectious Diseases; National Institute of Environmental Health Sciences/Environmental Protection Agency; and GlaxoSmithKline. |
Vol 127 - N° 1
P. 102-115 - janvier 2011 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?